Course Provider
Learning Objectives
Upon completion of this activity, participants should be better able to assess real-world data to identify barriers to optimal integration of novel therapies for frontline lower-risk myelodysplastic syndromes (LR-MDS) among hematology/oncology providers, including barriers unique to specific practice settings and disciplines
Upon completion of this activity, participants should be better able to evaluate the latest clinical safety and efficacy data for newly approved frontline LR-MDS therapies
Upon completion of this activity, participants should be better able to apply evidence-based strategies for effective integration, dosing, titration, and monitoring of novel therapies for LR-MDS
Upon completion of this activity, participants should be better able to employ multidisciplinary approaches for prevention, prompt recognition and management of adverse events with novel frontline LR-MDS treatments